logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10894023 B1

PDFFull Text
Expired
Date of Patent:
Jan. 19, 2021

Filed:

Jun. 20, 2019

Oral ph independent dosage formulation for treating neurodegenerative disorders

Applicants:

Center Laboratories, Inc., Taipei, TW;

Medical and Pharmaceutical Industry Technology and Development Center, New Taipei, TW;

Inventors:

Meng-Ju Lee, Taipei, TW;

Shu-Hsien Chang, Taipei, TW;

Chih-Chiang Yang, Taipei, TW;

Yuan-Chih Le, New Taipei, TW;

Tse-Ching Lin, New Taipei, TW;

Ko-Chiang Chen, New Taipei, TW;

Lai-Cheng Chin, Taipei, TW;

Tai-Yin Ke, New Taipei, TW;

Pei-Ying Liao, New Taipei, TW;

Assignee:

CENTER LABORATORIES, INC., Taipei, TW;

Attorney:
Primary Examiner:

Sin J Lee

Int. Cl.
CPC ...
A61K 31/13 (2006.01); A61K 31/445 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61K 9/48 (2006.01); A61K 9/00 (2006.01); A61P 25/16 (2006.01); A61P 25/14 (2006.01); A61P 25/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/13 (2013.01); A61K 9/0053 (2013.01); A61K 9/1652 (2013.01); A61K 9/1676 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 9/5084 (2013.01); A61K 31/445 (2013.01); A61P 25/14 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01);
Abstract

Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.

Find Patent Forward Citations

Lee, Meng-Ju. (2021). Oral ph independent dosage formulation for treating neurodegenerative disorders (U.S. Patent No. 10894023). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10894023

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…